



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

GFH7 Recombinant Human EG-VEGF

Description

Endocrine Gland-derived Vascular Endothelial Growth Factor (EG-VEGF) is an angiogenic growth factor that is expressed in the ovaries, testis, adrenal, and placental tissues. EG-VEGF has mitogenic, chemoattractive, and antiapoptotic functional roles. EG-VEGF signaling is mediated through binding the G protein-coupled receptors prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2). Polycystic ovaries display strong EG-VEGF expression that is associated with increased angiogenesis and cyst formation, which could lead to the formation of polycystic ovary syndrome and infertility.

Length	86 aa
Molecular Weight	9.7 kDa
Source	E. coli
Accession Number	P58294
Purity	≥95% determined by reducing and non-reducing SDS-PAGE


Specifications

Alternative Names	Endocrine Gland-derived Vascular Endothelial Growth Factor, prokineticin 1, PROK1
Biological Activity	Human EG-VEGF is fully biologically active when compared to standard. The activity is determined by the dose-dependent proliferation of MIA PaCa-2 cells and it is typically 1 - 4 µg/ml. This corresponds to an expected specific activity of 1 x 10 ³ units/mg. There is no data currently available.
Endotoxin Level	≤1.00 EU/µg as measured by kinetic LAL
Formulation	Lyophilized from a sterile (0.2 micron) filtered aqueous solution containing 0.1% Trifluoroacetic Acid (TFA)
AA Sequence	AVITGACERD VQCGAGTCCA ISLWLRGLRM CTPLGREGEE CHPGSHKVPF FRKRKHHTCP CLPNLLCSRF PDGRYRCSMD LKNINF

Preparation and Storage

Reconstitution	Centrifuge vial before opening. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with sterile water at 0.1 mg/ml, which can be further diluted into other aqueous solutions.
Stability and Storage	12 months from date of receipt when stored at -20°C to -80°C as supplied. 1 month when stored at 4°C after reconstituting as directed. 3 months when stored at -20°C to -80°C after reconstituting as directed.

Data



Non-reducing (-) and reducing (+) conditions in a 4 - 20% Tris-Glycine gel stained with Coomassie Blue. 1 µg of protein was loaded in each lane. Human EG-VEGF has a predicted Mw of 9.7 kDa.